Outlook Therapeutics (OTLK) Set to Announce Quarterly Earnings on Thursday

Outlook Therapeutics (NASDAQ:OTLK) will be issuing its quarterly earnings data before the market opens on Thursday, May 16th. Analysts expect the company to announce earnings of ($0.88) per share for the quarter.

Outlook Therapeutics (NASDAQ:OTLK) last released its quarterly earnings data on Wednesday, February 14th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.20. On average, analysts expect Outlook Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Outlook Therapeutics Trading Down 3.4 %

OTLK opened at $7.73 on Friday. The stock’s fifty day simple moving average is $8.50 and its 200 day simple moving average is $8.58. Outlook Therapeutics has a 1-year low of $4.00 and a 1-year high of $40.60. The stock has a market cap of $100.59 million, a PE ratio of -1.93 and a beta of 0.28.

Wall Street Analyst Weigh In

Several analysts recently commented on OTLK shares. BTIG Research raised shares of Outlook Therapeutics from a “neutral” rating to a “buy” rating and set a $50.00 target price for the company in a report on Wednesday, March 27th. Chardan Capital upgraded shares of Outlook Therapeutics from a “neutral” rating to a “buy” rating and set a $60.00 target price for the company in a research report on Thursday, February 15th. Guggenheim upgraded shares of Outlook Therapeutics from a “neutral” rating to a “buy” rating and set a $40.00 price target on the stock in a research report on Thursday, January 25th. Brookline Capital Management upgraded shares of Outlook Therapeutics from a “hold” rating to a “buy” rating and set a $31.40 price objective for the company in a research report on Thursday, January 25th. Finally, Capital One Financial reaffirmed an “overweight” rating on shares of Outlook Therapeutics in a report on Friday, February 16th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $46.43.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.